Atrium Therapeutics, Inc.

NASDAQ:RNA

Biotechnology

Healthcare
$6.64 +1.28%

+$0.16 today

Market cap
$143.23M
Beta
0.42
P/E (TTM)
-3.3
EPS (TTM)
-$3.78
52W Low $11.40High $16.77

Volume 0.22M

Average 0.35M

RNA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Atrium Therapeutics, Inc.NASDAQ: RNA

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development of $16.66M in Q1 FY2026

Q1 FY2026 research & development was $16.66M.

Context

  • Research & development amounted to 288.7% of revenue in FY2025.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$16.66M-9.9% QoQ
Last fiscal yearDec 2025
$53.76M— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
53.76M USD
Year-over-year change
—

Research & Development vs competitors

How RNA compares with its peers on the latest reported figures

No competitor Research & Development figures are available to compare.

Atrium Therapeutics, Inc.

NASDAQ:RNA

Intrinsic Alpha fair value

Locked

Current Price

$6.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.